Press Resease

Biomarkers Market By Biomarker Type (Safety, Efficacy, and Validation), By Application (Diagnostic, Drug Discovery & Development, Personalized Medicine, and Others), and By Disease (Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 18-Sep-2019 Category: Biotechnology Report Format : PDF Pages: 110 Report Code: ZMR-4750 Status : Published

Global biomarkers market expected to generate around USD 108.4 billion by 2025, at a CAGR of around 14.8% between 2019 and 2025. A biomarker is a substance that can be introduced among organisms to inspect organ functions or other aspects of their health.

Description

The report covers a forecast and an analysis of the biomarkers market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes the drivers and restraints of the biomarkers market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the biomarkers market on a global level.

In order to give the users a comprehensive view of the biomarkers market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Biomarkers Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launch, agreements, partnerships, collaborations & joint ventures, research & development, technology, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the biomarkers market by segmenting it based on biomarker type, application, disease, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some key players in the global biomarkers market are Agilent Technologies, F. Hoffmann-La Roche, Epigenomics, Abbott, Thermo Fisher Scientific, Johnson & Johnson, Siemens Healthcare, Bio-Rad Laboratories, and Qiagen.

This report segments the global biomarkers market into:

Global Biomarkers Market: Biomarker Type Analysis

  • Safety Biomarkers
  • Efficacy Biomarkers
  • Validation Biomarkers

Global Biomarkers Market: Application Analysis

  • Diagnostic
  • Drug Discovery and Development
  • Personalized Medicine
  • Others

Global Biomarkers Market: Technology Analysis

  • Cancer
  • Cardiovascular Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Others

Global Biomarkers Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Biomarkers Market, 2016-2025 (USD Billion)
    • 2.2. Global Biomarkers Market: Snapshot
  •  
  • Chapter 3. Biomarkers Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of chronic diseases
      • 3.2.2. Technological advancements
    • 3.3. Market Restraints
      • 3.3.1. Reimbursement policies
    • 3.4. Opportunities
      • 3.4.1. Growing Funding for biomarkers
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by Biomarker Type
      • 3.6.2. Market attractiveness analysis, by Application
      • 3.6.3. Market attractiveness analysis, by Disease
      • 3.6.4. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Biomarkers Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Biomarkers Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  •  
  • Chapter 5. Global Biomarkers Market - Biomarker Type Analysis
    • 5.1. Global Biomarkers Market: Biomarker Type overview
      • 5.1.1. Global Biomarkers Market Revenue, by Biomarker Type, 2018 and 2025
    • 5.2. Safety Biomarkers
      • 5.2.1. Global Biomarkers Market for Safety Biomarkers, 2016-2025 (USD Billion)
    • 5.3. Efficacy Biomarkers
      • 5.3.1. Global Biomarkers Market for Efficacy Biomarkers, 2016-2025 (USD Billion)
    • 5.4. Validation Biomarkers
      • 5.4.1. Global Biomarkers Market for Validation Biomarkers, 2016-2025 (USD Billion)
  •  
  • Chapter 6. Global Biomarkers Market - Application Analysis
    • 6.1. Global Biomarkers Market: Application overview
      • 6.1.1. Global Biomarkers Market Revenue, by Application, 2018 and 2025
    • 6.2. Diagnostic
      • 6.2.1. Global Biomarkers Market for Diagnostic, 2016-2025 (USD Billion)
    • 6.3. Drug Development
      • 6.3.1. Global Biomarkers Market for Drug Development, 2016-2025 (USD Billion)
    • 6.4. Personalized Medicine
      • 6.4.1. Global Biomarkers Market for Personalized Medicine, 2016-2025 (USD Billion)
    • 6.5. Others
      • 6.5.1. Global Biomarkers Market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 7. Global Biomarkers Market - Disease Analysis
    • 7.1. Global Biomarkers Market: Disease overview
      • 7.1.1. Global Biomarkers Market Revenue, by Disease, 2018 and 2025
    • 7.2. Cancer
      • 7.2.1. Global Biomarkers Market for Cancer, 2016-2025 (USD Billion)
    • 7.3. Cardiovascular Diseases
      • 7.3.1. Global Biomarkers Market for Cardiovascular Diseases, 2016-2025 (USD Billion)
    • 7.4. Neurological Diseases
      • 7.4.1. Global Biomarkers Market for Neurological Diseases, 2016-2025 (USD Billion)
    • 7.5. Immunological Diseases
      • 7.5.1. Global Biomarkers Market for Immunological Diseases, 2016-2025 (USD Billion)
    • 7.6. Others
      • 7.6.1. Global Biomarkers Market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 8. Global Biomarkers Market- Regional Segment Analysis
    • 8.1. Global Biomarkers Market: regional overview
      • 8.1.1. Global Biomarkers Market Revenue, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
      • 8.2.2. North America Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
      • 8.2.3. North America Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.2.4.2. The U.S. Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.2.4.3. The U.S. Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.2.5. Canada
        • 8.2.5.1. Canada Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.2.5.2. Canada Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.2.5.3. Canada Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
      • 8.3.2. Europe Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
      • 8.3.3. Europe Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.3.4. The U.K.
        • 8.3.4.1. U.K. Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.3.4.2. U.K. Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.3.4.3. U.K. Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.3.5. Germany
        • 8.3.5.1. Germany Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.3.5.2. Germany Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.3.5.3. Germany Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.3.6.2. France Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.3.6.3. France Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.3.7.2. Rest of Europe Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.3.7.3. Rest of Europe Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
      • 8.4.2. Asia Pacific Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
      • 8.4.3. Asia Pacific Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.4.4. China
        • 8.4.4.1. China Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.4.4.2. China Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.4.4.3. China Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.4.5.2. Japan Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.4.5.3. Japan Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.4.6. India
        • 8.4.6.1. India Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.4.6.2. India Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.4.6.3. India Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.4.7.2. Rest of Asia Pacific Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.4.7.3. Rest of Asia Pacific Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
      • 8.5.2. Latin America Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
      • 8.5.3. Latin America Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.5.4.2. Brazil Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.5.4.3. Brazil Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
        • 8.5.5.2. Rest of Latin America Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
        • 8.5.5.3. Rest of Latin America Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Biomarkers Market Revenue, by Biomarker Type, 2016-2025 (USD Billion)
      • 8.6.2. The Middle East and Africa Biomarkers Market Revenue, by Application, 2016-2025 (USD Billion)
      • 8.6.3. The Middle East and Africa Biomarkers Market Revenue, by Disease, 2016-2025 (USD Billion)
  •  
  • Chapter 9. Company Profile
    • 9.1. Agilent Technologies
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Therapy portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. F. Hoffmann-La Roche
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Therapy portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Epigenomics
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Therapy portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Abbott
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Therapy portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Thermo Fisher Scientific
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Therapy portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Johnson & Johnson
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Therapy portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Siemens Healthcare
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Therapy portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Bio-Rad Laboratories
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Therapy portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Qiagen
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Therapy portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments

Methodology

Free Analysis

A biomarker is a substance that can be introduced among organisms to inspect organ functions or other aspects of their health. A biomarker is objectively evaluated and measured as an indication of typical pathogenic processes, biological processes, or pharmacologic responses to therapeutic interventions. Biomarkers are genetic molecules produced either by human tissues or tumor cells in response to cancer. These molecules are then evaluated and measured as a mark of cancerous processes inside the body. Biomarkers are widely used in the management and detection of diseases in the patient population.

The growing prevalence of cancer and cardiovascular diseases, increasing healthcare expenditure for the diagnosis and treatment of chronic diseases are projected to fuel the global biomarkers market. Furthermore, the encouraging initiative by government and high adoption of technically advanced products will also boost the biomarker market in the future.

Global Biomarkers Market

The global cancer biomarkers market is fragmented based on biomarker type, application, and disease. Based on biomarker type, the biomarkers market is categorized into safety, validation, and efficacy biomarkers. Based on application, the biomarkers market includes personalized medicine, diagnostic, drug discovery and development, and others. By disease, the biomarkers market comprises immunological diseases, cancer, neurological diseases, cardiovascular diseases, and others.

North America dominated the biomarkers market globally in 2018 and is likely to remain dominant over the forecast time period as well. This regional dominance can be attributed to the regional presence of major pharmaceutical and biotechnology companies, increasing adoption of the latest technologies, and established healthcare infrastructure. The Asia Pacific region is expected to record high growth in the biomarkers market globally in the years ahead. The growing support of the regional governments for drug discovery and development programs and large patient pool are the major factors boosting the biomarkers market development in the Asia Pacific.

Some key players in the global biomarkers market are Agilent Technologies, F. Hoffmann-La Roche, Epigenomics, Abbott, Thermo Fisher Scientific, Johnson & Johnson, Siemens Healthcare, Bio-Rad Laboratories, and Qiagen. The aggregate investments by the major companies are made in their R&D activities to improve the product portfolio, which is projected to boost the biomarkers market growth in the future. For instance, in November 2016, Thermo Fisher Scientific added four items in its product portfolio for cancer research. These new products include the Oncomine Immune Response Research Assay, which is designed to cross-examine microenvironment of a tumor and identify prognostic biomarkers for immunotherapy clinical research trials.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com